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Abstract  99 
 100 
Background: Strict criteria for recombinant tissue plasminogen activator (rtPA) eligibility are 101 
stipulated on licences for use in ischaemic stroke, however, practitioners may also add non-standard 102 
rtPA criteria. We examined eligibility criteria variation in 3 English-speaking countries including use 103 
of non-standard criteria, in relation to rtPA treatment rates. 104 
  105 
Methods:  Surveys were mailed to 566 eligible hospitals in Australia (AUS), United Kingdom (UK) and 106 
the United States (USA). Criteria were pre-classified as standard (approved indication and 107 
contraindications ) or non-standard (approved  warning or researcher ‘decoy’). Percentage for 108 
criterion selection was calculated/compared; linear regression was used to assess the association 109 
between use of non-standard criteria and rtPA treatment rates, and to identify factors associated 110 
with addition of non-standard criteria.  111 
 112 
Results:  Response rates were 74% AUS, 65% UK, and 68% USA; mean rtPA treatment rates were 113 
8.7% AUS, 12.7% UK and 8.7% USA. Median percentage of non-standard inclusions was 33% (all 3 114 
countries) and included National Institutes of Health Stroke Scale (NIHSS) scores >4, computed 115 
tomography (CT) angiography documented occlusion, and favourable CT perfusion. Median 116 
percentage of non-standard exclusions was 25% AUS, 28% UK, and 60% USA, and included 117 
depressed consciousness, NIHSS>25, and use of antihypertensive infusions. No AUS or UK sites 118 
selected 100% of standard exclusions.  119 
 120 
Conclusions: Non-standard criteria for rtPA eligibility was evident in all three countries and could, in 121 
part, explain comparably low use of rtPA. Differences in the use of standard criteria may signify 122 
practitioner intolerance for those derived from original efficacy studies that are no longer relevant. 123 
 124 
  125 
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Introduction  126 
Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) has been shown to 127 
be safe and effective, and is one of the few evidence based treatments for acute ischaemic stroke.[1-128 
5] Currently, the percentage of patients with ischaemic stroke receiving rtPA varies globally, with 7% 129 
treated in the stroke centre certified United States of America (USA) hospitals,[6] 7% in Australia 130 
(AUS)[7] and 12% treated in the United Kingdom (UK) .[8]  The narrow time frame for therapeutic 131 
administration, which in the UK and AUS is within 4.5 hours of symptom onset and in the USA is 132 
within 3 (approved indication ) or 4.5 (guidelines) hours, is one main factor for low treatment rates. 133 
However, improved rtPA treatment rates are possible when internal hospital organisational factors 134 
are addressed,[9-12] and when regional stroke systems are operationalised to support patients with 135 
acute stroke.[13-16] 136 
 137 
Eligibility criteria for rtPA are largely derived from clinical trials with the aim of producing similar 138 
beneficial outcomes in routine practice. However, the addition of local or “site-specific” (non-139 
standard) eligibility criteria may result in otherwise eligible patients not receiving rtPA. There is a 140 
growing evidence base on the additional reasons for low rtPA treatment rates, including the fit 141 
between eligibility criteria and actual patient selection practices.[17-19] In particular, many of the 142 
criteria used in clinical trials may no longer be relevant given that the drug was first approved over 143 
20 years ago.[20-22] Mounting evidence from pooled analyses, observational studies and clinical 144 
trials, some studying an extended time window of 4.5hours and practices less adherent with 145 
standard criteria, suggests that rtPA can be delivered safely to patients previously deemed 146 
ineligible.[22-31] 147 
 148 
The eligibility criteria for rtPA administration varies between countries.[32-35] The European and 149 
Australian guidelines share many similarities, but these differ substantially from the USA guidelines, 150 
and the USA guidelines vary significantly from the drug’s approved indications and contraindications 151 
Varying criteria between national drug regulatory bodies, professional organisations, and individual 152 
hospital protocols challenges international consensus on what constitutes patient eligibility for 153 
treatment. There is an urgent need to understand these issues, including the addition of non-154 
standard criteria for selecting patients eligible for rtPA treatment. The aims of this study were to: 1) 155 
describe the criteria for patient selection for rtPA treatment by country; 2) to determine the 156 
association between the use of non-standard criteria and rtPA treatment rates in three different 157 
countries; and, 3) to identify the organisational factors associated with the addition of non-standard 158 
criteria. 159 
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 161 
Methods 162 
Ethics approval was obtained from the following institutions for the conduct of this study:  Eden 163 
Hospital, Castro Valley California (USA coordinating centre), the University of Central Lancashire (UK 164 
coordinating centre), and the Australian Catholic University (Australian, and overall international 165 
coordinating centre). We undertook a cross-sectional survey of rtPA eligibility and treatment 166 
practices within hospitals in Australia, the UK and the USA that routinely used rtPA for management 167 
of acute stroke patients.   The survey was conducted between 2013-2016 and analysed in 168 
2017. 169 
 170 
Hospital selection 171 
All hospitals in AUS and in the UK known to provide rtPA for acute ischaemic stroke were eligible for 172 
the study and were identified via the Stroke Foundation Organisational Survey[36] and The Sentinel 173 
Stroke National Audit Programme (SSNAP), respectively. In the USA, stroke centre hospitals were 174 
included based on the following inclusion criteria: 1) nationally certified by The Joint Commission for 175 
a minimum of 12 months at the time of survey mailing; 2) use of an organised acute stroke team in 176 
the approach to emergency diagnosis and treatment; and, 3) formal identification by policy and 177 
procedure of eligibility criteria for rtPA treatment.  178 
 179 
Survey distribution  180 
Within each hospital, one eligible staff member was identified to complete the survey: the Stroke 181 
Unit Co-ordinator in AUS and the USA and the SSNAP lead contact for the Trust in the UK Identified 182 
staff who were approached by mail (AUS and USA) or email (UK) with a letter inviting them to 183 
participate in the survey along with a copy of the questionnaire. Prior to this invitation, an advanced 184 
letter was sent to notify potential participants of the pending survey as a response aiding 185 
strategy.[37] Participation was voluntary and consent was implied by completion and return of the 186 
questionnaire. Completed questionnaires were returned via post, fax or completed and returned 187 
electronically. Non-respondents were followed-up by email or phone at six weeks and eight weeks in 188 
AUS and the UK. In the USA follow-up consisted of a second and third mail out at eight and 16 weeks 189 
from the initial mail out date.  190 
 191 
Survey content and development 192 
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The survey was originally designed for study in the USA and included both standard criteria for rtPA 193 
use in stroke patients (criteria stipulated by the USA rtPA approved indications and contraindications  194 
and/or guidelines) and non-standard criteria (i.e. decoys derived from interviews with both expert 195 
users and community neurologists in the USA). This survey was then tailored for use in AUS and UK 196 
by adding criteria specified by the relevant country: i) manufacturer, ii) drug regulatory body, and iii) 197 
stroke clinical guidelines (referred collectively as ‘practice recommendations’ hereafter). The 198 
Australian and UK version of the survey was pre-tested with a panel of experts (Neurologists, Stroke 199 
Clinicians and Stroke Nurses) to identify any ambiguous questions and to recommend further decoy 200 
criteria. All three versions of the surveys consisted of two main sections; one section listed all the 201 
inclusion criteria, and one section listed all the exclusion criteria. Participants were instructed to 202 
select all of the criteria that were used at their hospital to assess if patients are eligible for rtPA.  203 
Additional space was provided for participants to write in criteria that were not included on the 204 
questionnaire. Information was also collected on organisational factors which included type of 205 
stroke service (tertiary / non-tertiary referral centre), number of beds, number of ischaemic stroke 206 
admissions in the last 12 months, rtPA treatments in the last 12 months, door-to-needle time and 207 
who was involved in the selection and decision-making process for rtPA. 208 
 209 
Data Analysis  210 
Descriptive analyses were used to summarise the self-reported characteristics of the stroke services 211 
by country. Criteria for patient selection for rtPA were pre-classified as either “standard” (an 212 
inclusion or exclusion specified by country practice recommendations) or “non-standard” (warnings 213 
specified by country practice recommendations or decoy criteria developed by the researchers).  To 214 
determine criteria being used, the percentage of respondents that selected each criterion was 215 
calculated. For each hospital, the proportion of standard and nonstandard criteria of the total 216 
criteria was calculated. The proportion calculated for each hospital was summarised for each 217 
country and reported as a median percentage. Criteria added by respondents were independently 218 
reviewed by study investigators (LC, HH, AA), and classified to existing groups if meanings were 219 
similar or classified as non-standard criteria if meanings were unique. Treatment rates were 220 
calculated for each hospital using the number of annual rtPA treatments reported, divided by the 221 
number of annual ischemic stroke admissions, multiplied by 100.  Independent Student t-tests and 222 
one-way analysis of variance (ANOVA) were undertaken to examine the associations between pre-223 
specified stroke service variables (hospital setting [tertiary/non-tertiary] and door to needle times) 224 
and rtPA treatment rates in each country.  Linear regression analyses were conducted for each of 225 
the countries to assess associations between non-standard criteria and rtPA treatment rates. Linear 226 
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regression models were developed using preselected variables to identify organisational factors 227 
associated with the addition of non-standard criteria in each country. Analyses were conducted with 228 
Stata version 14. 229 
 230 
Results 231 
The response rates per country were 68% (AUS 74% (63/85), UK 65% (93/144) and USA 68% 232 
(229/337).  Tertiary hospital staff made up 39% of respondents overall (AUS 46%; UK 53%; USA 29%), 233 
with 38% of AUS respondents and 69% of USA respondents reporting comprehensive stroke centre 234 
(CSC) capabilities (CSC status was not reported on the UK survey) (Supplement Table A). Decision 235 
makers for treatment with rtPA in AUS and the USA were most commonly neurologists (84% and 236 
87%, respectively), whilst the majority of UK respondents selected stroke (usually geriatrician) 237 
physicians (99%).  Interestingly, 31% of USA centres would only accept an rtPA order from a 238 
neurologist.  Telemedicine was not used in 68% and 39% of AUS and UK respondents respectively 239 
(not collected on USA survey) (Supplement Table A).  240 
 241 
Differences in rtPA Treatment Rates 242 
Of responding stroke centres, 60 (95%) AUS, 77 (83%) UK, and 184 (80%) USA centres included both 243 
their annual ischaemic stroke patient volumes and their annual rtPA treatment volumes enabling 244 
calculation of rtPA treatment rates.  Mean rtPA treatment rate for Australia, UK and USA were 8.7% 245 
(SD=5.8), 12.7% (SD=4.7) and 8.7% (SD=6.4), respectively. Supplement Table B shows differences in 246 
rtPA treatment rates by tertiary care designation and door-to-needle times. Rates for rtPA 247 
treatments were consistently higher for tertiary than non-tertiary hospitals and increased with 248 
shorter door-to-needle time for all three countries, although differences in mean rates were only 249 
significantly different for USA (F 7.64; p<0.001).  250 
Selection of Inclusion Criteria for rtPA Treatment 251 
The median percentage of standard criteria selected by USA (50%; IQR 25) respondents was less 252 
than that selected by AUS (100%; IQR 33) and UK (100%; IQR 0) respondents. The median 253 
percentage of non-standard criteria selected by respondents from all three countries was 33%. 254 
 255 
Table 1 lists standard and non-standard inclusion and exclusion criteria and their rates of selection 256 
by country. The standard USA approved  inclusion criterion, ‘Ability to start rtPA within 3 hours from 257 
symptom onset’ was selected by almost a quarter of USA respondents.  The non-standard criterion 258 
for limiting inclusion to patients with National Institutes of Health Stroke Scale scores greater than 4 259 
points was selected by about half of respondents from AUS (49%) and the UK (51%), and 35% of USA 260 
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respondents.  The non-standard criterion for a favourable computed tomographic (CT) perfusion 261 
(CTP) scan in patients inside the window for rtPA treatment was selected by 22% of AUS and 19% of 262 
USA respondents, whereas only 11% of UK respondents selected this criterion.  Additionally, 21% 263 
and 26% of AUS and USA respondents respectively required evidence of occlusion on CT angiography 264 
(CTA) as an rtPA non-standard inclusion criterion, compared to 16% of UK respondents.   265 
  266 
Selection of Exclusion Criteria for rtPA Treatment 267 
The median percentage of standard exclusion criteria selected by USA (82%; IQR 18) respondents 268 
was higher than that selected by AUS (66%; IQR 24) and UK (64%; IQR 25) respondents. The median 269 
percentage of non-standard exclusions selected by USA respondents (60%; IQR 60) was again higher 270 
than that selected by AUS (25%; IQR 19) and UK (28%; IQR 17) respondents.  271 
 272 
There were no respondents within AUS or the UK that selected all their country’s standard exclusion 273 
criteria, and all AUS and UK respondents added non-standard exclusion criteria.  Both “NIHSS > 25” 274 
and “altered level of consciousness (obtunded, stuporous, or comatose)” were selected by 62% and 275 
42% of AUS and UK respondents respectively, whereas 31% of USA respondents reported that their 276 
hospital excluded patients with NIHSS > 25, and 7% of USA respondents’ hospitals excluded patients 277 
with altered level of consciousness.  Additionally, 29%, 24% and 7% of AUS, UK and USA respondents 278 
indicated that their hospital excludes patients from rtPA treatment if they require a continuous IV 279 
infusion of an antihypertensive agent.  Patients with large vessel occlusion (LVO) were considered an 280 
exclusion for rtPA treatment by 14% of USA respondents, in favour of endovascular management, 281 
whereas 1.6% and 8.6% of AUS and UK respondents respectively reported that their hospitals 282 
exclude LVO from rtPA treatment in favour of endovascular treatment.  Age greater than 80 years 283 
was listed as an exclusion by 13% and 16% of AUS and USA respondents respectively, compared to 284 
only 3% of UK respondents, regardless of whether treating within the 3 or 4.5-hour treatment 285 
window. 286 
 287 
Relationship of Non-Standard Criteria to rtPA Treatment 288 
As the number of non-standard inclusions and exclusions increased, rtPA treatment rates slightly 289 
decreased in all three countries. As the number of non-standard criteria increased by one the rtPA 290 
rate decreased by 0.48% (p=0.05), 0.31% (p=0.07) and 0.16% (p=0.13) for AUS, UK and the USA, 291 
respectively. 292 
 293 
Association Between Factors and the Addition of Non-Standard Criteria 294 
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Factors significantly associated with the addition of non-standard criteria in the USA were as follows: 295 
non-tertiary hospital setting (-1.72 [95%CI -3.25, -0.20]); p-value=0.03); average door-to-needle time 296 
greater than 60 minutes (3.57 [95%CI -0.38, 6.75]; p-value=0.023) and adherence to 3-hour 297 
treatment window (-2.44 [95%CI -4.30, -0.60]); p-value=0.01). No factors were significantly 298 
associated with the addition of non-standard criteria in AUS or in the UK (Supplement Table C). 299 
 300 
Discussion 301 
Our study found that clinicians commonly develop and use non-standard criteria for selection of rtPA 302 
eligible patients. Importantly, both AUS and the UK have greater numbers of standard criteria 303 
compared to the USA, yet participants from these countries use more non-standard criteria than in 304 
the USA. The use of non-standard exclusion criteria has been investigated in other studies, however, 305 
the aims of most of these studies were to identify the impact of non-standard eligibility criteria on 306 
early clinical outcomes such as rates of symptomatic intracerebral haemorrhage (sICH).[20-23,38]   307 
To the best of our knowledge, our study appears to be the only one examining clinicians’ formal 308 
protocol additions of non-standard criteria in relation to rtPA treatment rates.  309 
 310 
There were a number of differences in the criteria between countries relating to the use of both 311 
standard and non-standard exclusion criteria. Differences in use of standard criteria between 312 
countries could signify clinical uncertainty, conflicting research evidence, or perhaps an intolerance 313 
for continued use of criteria that supported efficacy studies of rtPA in acute ischemic stroke but may 314 
not be relevant outside a phase III clinical trial.  For example, both severe neurologic disability and 315 
blood glucose limits were considered warnings but not contraindications on the former (prior to 316 
February 2015) [39] USA label for rtPA, whereas the Australian and UK labels continue to stipulate 317 
specific limits from which to exclude rtPA treatment. Interestingly, the February 2015 USA Food and 318 
Drug Administration (FDA) rtPA approved label [39] removed severe neurologic disability as a 319 
precaution, based on findings from the original National Institute of Neurological Disorders and 320 
Stroke rtPA Stroke Study that showed significant improvement in severe disability patients treated 321 
with rtPA compared to placebo.[40]  Similarly, the 2015 USA FDA approved label [39] no longer cites 322 
blood glucose values as warnings, as these are easily monitored and managed in both the pre-323 
hospital and emergency department settings.  324 
 325 
The use of some standard exclusions was fewer than expected in both AUS and the UK. For example, 326 
less than 25% of participants in these countries selected the standard exclusion, patients with any 327 
history of prior stroke and concomitant diabetes. Although the use of rtPA has not been approved in 328 
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Europe for these patients, registry studies have shown that while this criterion may have been 329 
important in the ECASS-3 efficacy study,[2] it may not be relevant to real-world practice and does 330 
not jeopardise the safe treatment of patients with rtPA.[41-42] While trial methods do provide a 331 
degree of certainty about what results to expect in a similar population, use of approved therapies in 332 
the real world often calls for less exclusivity.[43]  333 
 334 
It has been recognised internationally that selection criteria may be too restrictive and some have 335 
expressed concerns that the evidence underpinning the need to include certain criteria is not 336 
robust.[20-28,43-45]  The 2015 USA FDA labeling requirements for prescription drugs, commonly 337 
referred to as the ‘Physician Labelling Rule’ (PLR), state ‘No implied claims or suggestions of drug use 338 
may be made if there is inadequate evidence of safety or a lack of substantial evidence of 339 
effectiveness,[46] meaning that unless there is high level evidence to support a safety concern, it 340 
should not be considered a contraindication. The USA FDA’s PLR requirements significantly reduced 341 
the number of USA exclusion criteria to seven in 2015, with previous stroke, seizure at onset, and 342 
history of intracranial haemorrhage removed; additionally, blood pressure cut off levels, as well as 343 
lab values for bleeding diathesis were also removed in favour of relying on evidence-based 344 
guidelines to set these values.[39]  The 2015 USA FDA label also removed precautions for severe 345 
neurologic deficit, major early infarct signs, minor neurologic deficit, and rapidly improving 346 
symptoms.[39[  Interestingly, the majority of the USA criteria that were removed, currently remain 347 
on the European and Australian labels, and we believe that this calls for a more thorough evaluation 348 
of whether these criteria are truly valid perhaps using the processes established by The Re-349 
examining Acute Eligibility for Thrombolysis (TREAT) Task Force is comprised members of the original 350 
NINDS rtPA Stroke Trial Steering Committee,[47] especially with sICH rates from more recent studies 351 
and registries commonly at less than 3%.[2,48-52] The investigators of a recent study which aimed to 352 
assess whether adherence to drug labels is associated with efficacious patient outcomes concluded 353 
that product labels need to be revised, finding that adherence with product labels is highest with 354 
less efficacious interventions.[53] 355 
 356 
Limitations 357 
This study carries the limitations of survey research such as the risk of response and recall bias. First, 358 
we assume that findings submitted are truthful and accurately reflect the practice at the 359 
participating stroke centres, although this may not be the case. We also acknowledge that some 360 
items such as aortic arch dissection were not listed as criteria in the questionnaire for participants to 361 
select. Additionally, surveys do not provide the meaning or context behind a response. Therefore, 362 
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we are limited in our ability to provide an understanding of why and how clinicians make certain 363 
decisions including their areas of clinical or research uncertainty.[54] Lastly, although this 364 
questionnaire was personally addressed to Stroke Unit Coordinators, a variety of professional groups 365 
responded; while this was anticipated and encouraged by our instructions to ‘collaborate with 366 
colleagues, who are involved in the decision-making and administration of rtPA for stroke patients,’ it 367 
does potentially introduce a source of differential error and measurement error. Furthermore, this is 368 
a highly dynamic field, with new imagining criteria re-defining reperfusion strategies at different 369 
time points.[55,56] Therefore, it would be worthwhile to repeat this study as the reperfusion 370 
paradigm shifts. 371 
 372 
Strengths 373 
This research provides novel data about rtPA international administration practices and the 374 
differences in the use of selection criteria in three different countries, two with similar healthcare 375 
systems (AUS/UK), and the USA with a largely private health system. The survey had a reasonable 376 
response rate for all three countries which adds external validity to the findings, and our survey tools 377 
were extensively pre-tested with experts contributing face validity to our methods.  378 
 379 
Conclusion  380 
This study provides novel, and somewhat provocative data about the criteria used to select patients 381 
for rtPA across three English-speaking countries, in particular, the relatively common use of non-382 
standard criteria for rtPA eligibility which may contribute in part, to low rtPA treatment rates.  383 
  384 
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Table 1  Reported rt-PA eligibility criteria by country 
 INCLUSION CRITERIA AUS UK USA  
 N=63 N=93 N=229 
Standard all (n=2) n(%) n(%) n(%) 
 Clinical diagnosis of acute ischaemic stroke causing measurable neurological deficit 58 (92)  89 (96) 180 (79) 
 Exclusion of Intracranial haemorrhage by appropriate imaging techniques1 59 (94)  90 (97) NA 
Standard USA only (n=2)  
 Age > 18 years    57 (91)  81 (87) 179 (78) 
 Ability to start <3 hours from symptom onset    1 (1.6)  1 (1.1) 54 (24) 
Standard UK & AUS (n=1); Standard by USA Guidelines/Non-standard by USA Label   
 Ability to start <4.5 hours from symptom onset 62 (98)  92 (99) 172 (75) 
Non-standard all (n=4)  
 NIHSS > 4 31 (49)  47 (51) 80 (35) 
  Favourable CTP penumbra. 14 (22)  10 (11) 43 (19) 
 Occlusion on CTA 13 (21)  15 (16) 60 (26) 
 Age <80 years, for 3-4.5hr since onset 11 (18)  33 (36) 111(63)
 2 
(65.7) 
Non-standard USA (n=1)  
 Order for IV rtPA given only by a neurologist NA NA 71 (31) 
STANDARD EXCLUSION Criteria AUS UK USA 
Bleeding risk  n(%) n(%) n(%) 
Standard all (n=12) 
 Active Internal Bleeding 59 (94) 85 (91) 181 (79) 
 Clinical presentation suggestive of SAH, even if CT is normal 54 (86) 78 (83) 150 (66) 
 Known bleeding diathesis 51 (81) 75 (81) 160 (70) 
 INR >1.7  59 (94) 86 (93) 179 (78) 
 APTT greater than upper limit of normal on lab report 37 (59) 47 (51) 163 (71) 
 Prothrombin Time > 15 seconds  19 (30) 24 (26) 113 (49) 
 Platelet count of below 100,000/mm4 47 (75) 53 (57) 170 (74) 
 History of serious head trauma or ischaemic stroke within 3 months of this event 52 (83) 78 (84) 180 (79) 
 History of structural lesions including arteriovenous malformation, aneurysms or tumours 49 (78) 71 (76) 161 (70) 
 History of intracranial haemorrhage at any point in the past 45 (71) 72 (77) 194 (85) 
 Past major surgery or serious trauma in past 3 months 43 (68) 64 (69) 174 (76) 
 Evidence of intracranial haemorrhage on CT-scan 50 (79) 83 (89) NA3 
Standard USA only (n=1) 
 Systolic BP > 185 mm Hg and/or diastolic BP > 110 mm Hg at the time of rtPA treatment NA NA 181 (79) 
Standard AUS & UK only (n=10) 
 Significant bleeding disorder at present or within last 6 months 40 (64) 69 (74) NA 
 Recent arterial puncture at a non-compressible site 47 (75) 73 (79) 153 (67) 
 Neoplasm with increased risk of bleeding 35 (56) 60 (65) NA 
 Manifest or recent severe or dangerous bleeding 40 (64) 73 (79) NA 
 Severe uncontrolled arterial hypertension 40 (64) 60 (65) NA 
 Systolic BP >185 or diastolic BP >110 mm Hg, or aggressive (IV) management  49 (78) 54 (58) NA 
 History of gastrointestinal or urinary tract haemorrhage within 21 days 45 (71) 73 (79) 163 (71) 
 Recent (less than 10 days) traumatic CPR or obstetrical delivery 39 (62) 64 (69) NA 
 Patients receiving other intravenous thrombolytic agents 31 (49) 58 (62) NA 
 Any current use of anticoagulation regardless of coagulation study findings 14 (22) 15 (16) 51 (22) 
Stroke severity and/or disability  
Standard AUS & UK (n=4) 
 Symptoms beginning more than 4.5 hours / unknown onset time 48 (76) 72 (77) NA 
 Severe neurological disability e.g. NIHSS >25 39 (62) 39 (42) 70 (31) 
 Prior stroke within the last 3 months 37 (59) 58 (62) NA 
 Rapidly improving stroke symptoms, even if measurable disability remains 22 (35) 40 (43) 100 (44) 
Comorbidity  
Standard all (n=1) 
 Observed seizure at stroke onset 45 (71) 53 (57) 122 (53) 
Standard UK & AUS only(n=7) 
 Suspected post-myocardial infarction pericarditis 21 (33) 36 (39) 77 (34) 
 Acute pancreatitis 20 (32) 55 (59) NA 
 Suspicion of endocarditis 32 (51) 47 (51) 58 (25) 
 Severe liver disease, including hepatic failure, cirrhosis, portal hypertension & active hepatitis 35 (56) 58 (62) NA 
 Abnormal blood glucose; <50mg/dL (<2.8mmol/L) or >400mg/dL (22.2mmol/L) 53 (84) 53 (57) 133 (58) 
 Documented ulcerative gastrointestinal disease (last 3 months), oesophageal varices, arterial 
aneurysm, arterial/venous malformation 
40 (64) 73 (79) NA 
 Patients with any history of prior stroke and concomitant diabetes 9 (14) 19 (20.4) NA 
Demographics 
Standard UK & AUS only(n=1) 
 Age <18 years 38 (60) 59 (63) NA 
NON-STANDARD EXCLUSION Criteria AUS UK USA 
Bleeding risk (n=5) n (%) n (%) n (%) 
 Current use of novel anticoagulants (NOACS) 36 (57) 67 (72) 132 (58) 
 Use of continuous intravenous infusion to control blood pressure 18 (29) 22 (24) 17 (7.0) 
 Patients pre-treated with acetyl salicylic acid  1 (1.6) 7 (7.5) NA 
 On other antiplatelet medication4 NA NA 12 (5.2) 
 Other conditions deemed high risk for haemorrhage4 3 (4.8) 2 (2.2) NA 
Stroke severity and/or disability (n=4) 
 Level of consciousness severely depressed (obtunded, stuporous or comatose) 39 (62) 39 (42) 16 (7.0) 
 Minor neurological disability  23 (37) 29 (31) 59 (26) 
 History of previous ischaemic stroke at any point in the past 5 (7.9) 7 (7.5) NA 
 Large artery occlusion warranting primary intra-arterial treatment 1 (1.6) 8 (8.6) 31 (14) 
Comorbidity (n=11) 
 Pregnancy 47 (75) 38 (41) 112 (49) 
 Concurrent acute myocardial infarction 30 (48) 15 (16) 60 (26) 
 Serious, advanced or terminal illness4 8 (13) 0 NA 
 Suspected septic emboli4 8 (13) 0 NA 
 Elevated liver enzymes 4 (6.4) 17 (18) NA 
 Not observed, but suspected seizure at stroke onset 18 (29) 21 (23) 45 (20) 
 Pre-existing moderate to severe disability (mRS >3/4)4 7 (11) 9 (9.7) NA 
 Known hypersensitivity to Alteplase or gentamicin4 5 (7.9) 0 NA 
 Recent lumbar puncture 24 (38) 50 (54) 114 (50) 
 Myocardial infarction in last 3 months4 1 (1.6) 0 NA 
 Lactation or parturition in last 30 days4 1 (1.6) 0 NA 
Demographics(n=4) 
 Age >75 years 0 0 NA 
 Age > 80 years 8 (13) 3 (3.2) 36 (16) 
 Only to be used by physicians trained and experienced in the use of thrombolytic treat 11 (18) 40 (43) NA 
 Inability to obtain written informed consent for on-label treatment 5 (7.9) 3 (3.2) 21 (9.2) 
1 - This was specified as an exclusion on the USA survey and therefore not specified on inclusions. 2 – The 54 respondents that selected the standard 
USA criteria “Age <80 years, for 3-4.5hr since onset” were removed from the calculation. 3 - Haemorrhage on CT was specified as an exclusion on the 
USA survey, so these data were not collected. 4 - This was specified as an ‘other’ by respondents 
NA = not applicable refers to a criterion that was not pre-specified in the country-specific survey. 
SAH: Subarachnoid Haemorrhage; CT: Computed Tomography; CTP: Computed tomography perfusion; CTA: Computed tomography angiography; INR: 
International Normalised Ratio; APTT: Activated Partial Thromboplastin Time; BP: Blood Pressure; CPR: Cardiopulmonary Resuscitation; NIHSS: 
National Institute of Health’s Stroke Scale; mRS: Modified Rankin Scale; ROSIER: Recognition of Stroke in the Emergency Room Scale. 
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Supplement Table A  Key stroke service demographics 
 
 
 
 
 
 
 
  
*rt-PA protocols were required to participate in the survey. 
 
Hospital setting AUS 
(N=63)  
UK 
(N=93) 
USA 
(N=229) 
 n (%) 
Tertiary 29 (46) 49 (53) 66 (29) 
Non-tertiary 30 (48) 43 (46) 152 (66) 
Private 4 (6.4) 0  0  
Not Reported 0 1 (1) 11 (5) 
Stroke service     
Comprehensive 24 (38) Not Collected 157 (69) 
Primary 31 (49) Not Collected 64 (28) 
General hospital  8 (13) Not Collected 3 (1) 
Not Reported 0 Not Collected 5 (2) 
Level of telemedicine use     
Always 2 (3.2) 6 (6.5) Not Collected 
Often 8 (13) 17 (18) Not Collected 
Sometimes 9 (14) 33 (35.5) Not Collected 
Never 43 (68) 36 (39) Not Collected 
Unknown 1 (1.6) 0  Not Collected 
Not Reported 0 1 (1) Not Collected 
rt-PA protocol    
Yes 62 (98) 92 (99) NA* 
No 1 (1.6) 0 (0.0) NA* 
Not Reported 0 1 (1) NA* 
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Supplement Table B  Associations between service related factors and rtPA treatment rates 
 AUS UK USA 
Mean (SD) p-value n Mean (SD) p-value n Mean (SD) p-value N 
Hospital Setting1 
Non-Tertiary 
Tertiary 
 
7.62 (5.22) 
9.95 (6.22) 
 
0.120 
 
31 
29 
 
11.52 (4.77) 
13.69 (4.52) 
 
0.046 
 
36 
41 
 
7.94 (5.72) 
10.97 (7.68) 
 
0.005 
 
135 
48 
Average door to 
needle time2 
<45mins 
46-59mins 
≥60mins 
 
15.68 (9.21) 
9.79 (6.21) 
8.85 (5.09) 
 
0.131 
 
3 
9 
37 
 
14.88 (6.18) 
13.99 (4.00) 
11.90 (3.14) 
 
0.067 
 
20 
18 
28 
 
16.51 (7.35) 
10.75 (7.68) 
8.07 (5.89) 
 
<0.001 
 
7 
24 
151 
1 Independent Sample t-test, 2 One-way ANOVA 
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Supplement Table C  Factors associated with the addition of non-standard criteria 
 AUS 
N=49 
UK 
N=68 
USA 
N=184 
Variables entered in regression model Coefficients  
 
p-value Coefficients  
 
p-value Coefficients  
  
p-value 
Hospital Setting -0.29 (-2.84, 2.25)  0.817 -0.83 (-2.39,0.72) 0.287 -1.72(-3.25, -0.20) 0.03 
Service 0.06 (-2.35, 2.48) 0.958 NA  -0.28(-1.68, 1.10) 0.684 
Admission volume -0.00 ( -0.01, 0.01)     0.983    -0.01(-0.04,0.00) 0.434 0.00 (-0.00, 0.00) 0.187 
Average door to needle time (46mins to 59mins) -1.33(-5.52, 2.86) 0.525 1.13(-0.86,3.12) 0.262 2.51(-1.05, 6.07) 0.165 
Average door to needle time (>60mins) 0.60 (-3.34-4.54) 0.760 1.19(-0.67,3.05) 0.207 3.57 (0.38 ,6.75) 0.023 
Adherence to 3 hours NA  NA  -2.44(-4.30, -0.60) 0.01 
 
 
